Latest news with #VYNETherapeutics
Business Insider
26-04-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Roche Holding AG (RHHVF – Research Report) and VYNE Therapeutics (VYNE – Research Report) with bullish sentiments. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Roche Holding AG (RHHVF) Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG on April 24 and set a price target of CHF315.00. The company's shares closed last Friday at $318.07. Evans has an average return of 10.6% when recommending Roche Holding AG. According to Evans is ranked #6071 out of 9437 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $351.87 average price target, representing a 12.6% upside. In a report issued on April 16, Exane BNP Paribas also initiated coverage with a Buy rating on the stock with a CHF300.00 price target. LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on VYNE Therapeutics yesterday and set a price target of $6.00. The company's shares closed last Friday at $1.43. According to Katkhuda is a 5-star analyst with an average return of 14.5% and a 35.4% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Eledon Pharmaceuticals. VYNE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.19, a 324.0% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.
Yahoo
07-03-2025
- Business
- Yahoo
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Net loss: US$39.8m (loss widened by 42% from FY 2023). US$0.94 loss per share. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) exceeded analyst estimates by 3.1%. Looking ahead, revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 6.8% from a week ago. What about risks? Every company has them, and we've spotted 5 warning signs for VYNE Therapeutics (of which 2 are a bit unpleasant!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
